Hamed Dehghan

Publications (2)0 Total impact

• Source

  Available from: Mohsen Janghorbani

  Article: Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial.

  Vahid Shaygannejad, Mohsen Janghorbani, Fereshteh Ashtari, Hamed Dehghan
  [show abstract] [hide abstract]
  ABSTRACT: The aim of this preliminary study was to evaluate the effect of low-dose oral vitamin D in combination with current disease-modifying therapy on the prevention of progression of relapsing-remitting multiple sclerosis (RRMS). A phase II double-blind placebo-controlled randomized clinical trial conducted between October 2007 and October 2008 included 50 patients with confirmed RRMS aged 25 to 57 years and normal serum 25-hydroxyvitamin D. They were randomly allocated to receive 12 months of treatment with either escalating calcitriol doses up to 0.5 μg/day or placebo combined with disease-modifying therapy. Response to treatment was assessed at eight-week intervals. In both groups, the mean relapse rate decreased significantly (P < 0.001). In the 25 patients treated with placebo, the mean (SD) Expanded Disability Status Scale (EDSS) increased from 1.70 (1.21) at baseline to 1.94 (1.41) at the end of study period (P < 0.01). Average EDSS and relapse rate at the end of trial did not differ between groups. Adding low-dose vitamin D to routine disease-modifying therapy had no significant effect on the EDSS score or relapse rate. A larger phase III multicenter study of vitamin D in RRMS is warranted to more assess the efficacy of this intervention.
  Multiple sclerosis international. 01/2012; 2012:452541.
• Source

  Available from: Khodayar Golabchi

  Article: A Comparative Study of 25 (OH) Vitamin D Serum Levels in Patients with Multiple Sclerosis and Control Group in Isfahan, Iran.

  Vahid Shaygannejad, Khodayar Golabchi, Sepehr Haghighi, Hamed Dehghan, Amin Moshayedi
  [show abstract] [hide abstract]
  ABSTRACT: There is no study about correlation between vitamin D serum level and multiple sclerosis (MS) in Iran. So in this survey, we investigated the serum level of 25-hydroxy vitamin D in MS patients and compared it with controls in central region of Iran, an area with medium to high risk for MS disease, in spite of high sun exposure. A case-control study was conducted from July 1, 2008 to July 31, 2009. We enrolled 50 definitive MS patients, according to McDonald's criteria as case group and 50 matched controls. Our age limits were 15 to 55 years and those patients with estimated expanded disability status scale less than 5 were introduced to the study. We measured serum level of 25-hydroxy vitamin D and compared them between the two groups. We gathered 42 females and 8 males as case group and the same numbers as control group without significant age difference. The mean serum level of 25-hydroxy vitamin D in case and control groups were 48 and 62 nmol/L, respectively, and the difference was significant (P=0.036). Also, our study showed significant discrepancy between the two groups according to the rate of deficiency, insufficiency and normal range of vitamin D categories (P=0.021). We found the same results as those studies carried out in Europe and North America; i.e., lower serum vitamin D level in MS patients than that in normal population, in spite of sufficient sun exposure in Isfahan region.
  International journal of preventive medicine 01/2010; 1(3):195-201.